prostate cancer
Oncology · 2006–2024
No submission for this condition has carried consumer input, including the 4 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| leuprorelin acetate Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate, and central precocious puberty. | Nov 2024 | Recommended | none received |
| leuprorelin Treatment of locally advanced (Stage C) and metastatic (Stage D) prostate cancer. | Jul 2019 | Not recommended | none received |
| degarelix Treatment of locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate. | Mar 2017 | Recommended with restriction | none received |
| leuprorelin acetate Treatment of locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate. | Jul 2015 | Recommended | none received |
| degarelix Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate. | Jul 2010 | Recommended with restriction | no section in document |
| triptorelin embonate Treatment of locally advanced or metastatic carcinoma of the prostate. | Nov 2006 | Recommended with restriction | no section in document |
| triptorelin embonate Treatment of locally advanced or metastatic carcinoma of the prostate. | Nov 2006 | Recommended with restriction | no section in document |
What the PBS pays
$131M in government benefit over 2024–25, across 180,916 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| leuprorelin | $56.8M |
| leuprorelin acetate | $56.8M |
| degarelix | $10.6M |
| Triptorelin | $6.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| padeliporfinPadeliporfin for untreated localised prostate cancer | TA546 | not recommended | 2018-11 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| flutamideFLUTAMIN flutamide 250mg tablet blister pack | 1999 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.